Covered recipient · General Payments record
RAYMOND R BURGESS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,712.62
- Reported across 202 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $347.96 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $125.95 | 5 |
| Janssen Pharmaceuticals, Inc | $44.60 | 2 |
| Novo Nordisk AS | $37.64 | 2 |
| Lilly USA, LLC | $35.76 | 2 |
| Exact Sciences Corporation | $30.89 | 1 |
| PFIZER INC. | $21.80 | 1 |
| GlaxoSmithKline, LLC. | $19.09 | 1 |
| Inari Medical, Inc. | $16.92 | 1 |
| Medtronic, Inc. | $15.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.63 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103392241 | CMS |
| ABBVIE INC. | $26.10 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103392243 | CMS |
| ABBVIE INC. | $28.27 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103392245 | CMS |
| ABBVIE INC. | $18.59 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103392247 | CMS |
| ABBVIE INC. | $30.36 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103392249 | CMS |
| Exact Sciences Corporation | $30.89 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114602943 | CMS |
| GlaxoSmithKline, LLC. | $19.09 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116030110 | CMS |
| Inari Medical, Inc. | $16.92 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140066609 | CMS |
| Janssen Pharmaceuticals, Inc | $19.46 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077975674 | CMS |
| Janssen Pharmaceuticals, Inc | $25.14 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077975676 | CMS |
| Lilly USA, LLC | $16.89 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135355656 | CMS |
| Lilly USA, LLC | $18.87 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135360954 | CMS |
| Medtronic, Inc. | $15.31 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119584283 | CMS |
| Novo Nordisk Inc | $15.41 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096909677 | CMS |
| Novo Nordisk Inc | $22.23 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096616260 | CMS |
| PFIZER INC. | $21.80 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131806231 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.